{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T02:06:27Z","timestamp":1788228387793,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"SNUBH Research Fund","award":["00-2019-06-2022-0378"],"award-info":[{"award-number":["00-2019-06-2022-0378"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rifampicin is an important agent for tuberculosis treatment; however, it is often discontinued because of adverse reactions. The treatment regimen then can be administered as that for rifampicin-resistant tuberculosis, which can be toxic. We retrospectively reviewed 114 patients with drug-susceptible pulmonary tuberculosis who discontinued rifampicin due to adverse reactions during an 18\u00a0year period at a tertiary referral center, of which 92 (80.7%) exhibited favorable response. Hepatotoxicity was the leading cause of intolerance. Patients with a favorable response were younger and less likely to have comorbidities. The majority of patients were administered four medications during the intensive phase and three to four during the consolidative phase. For those with a favorable response, the median duration of treatment was 10.2\u00a0months and the most common intensive regimen was a combination of isoniazid, ethambutol, pyrazinamide, and fluoroquinolone (25%). The most common consolidation regimen was a combination of isoniazid, ethambutol, and fluoroquinolone (22.8%). Among the patients with a favorable response, two (2.2%) experienced recurrence after a follow-up of 3.4 (interquartile range 1.8\u20136.8) years. For patients with drug-susceptible pulmonary tuberculosis who do not tolerate rifampicin owing to its toxicity, a shorter regimen may be a useful alternative.<\/jats:p>","DOI":"10.1038\/s41598-023-38394-1","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T11:02:46Z","timestamp":1689159766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis"],"prefix":"10.1038","volume":"13","author":[{"given":"Hyung-Jun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Jin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Soo","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yoon","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon-Joo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Sun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Jae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon-Taek","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Ho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"38394_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S2213-2600(19)30418-7","volume":"8","author":"E Harding","year":"2020","unstructured":"Harding, E. WHO global progress report on tuberculosis elimination. Lancet Respir. Med. 8, 19. https:\/\/doi.org\/10.1016\/S2213-2600(19)30418-7 (2020).","journal-title":"Lancet Respir. Med."},{"key":"38394_CR2","doi-asserted-by":"publisher","first-page":"e17601","DOI":"10.1371\/journal.pone.0017601","volume":"6","author":"EW Tiemersma","year":"2011","unstructured":"Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G. & Nagelkerke, N. J. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE 6, e17601. https:\/\/doi.org\/10.1371\/journal.pone.0017601 (2011).","journal-title":"PLoS ONE"},{"key":"38394_CR3","unstructured":"World Health Organization. Global tuberculosis report, <https:\/\/www.who.int\/publications\/i\/item\/9789240037021> (2021)."},{"key":"38394_CR4","doi-asserted-by":"publisher","first-page":"8949","DOI":"10.1016\/S0021-9258(17)34269-2","volume":"253","author":"WR McClure","year":"1978","unstructured":"McClure, W. R. & Cech, C. L. On the mechanism of rifampicin inhibition of RNA synthesis. J. Biol. Chem. 253, 8949\u20138956 (1978).","journal-title":"J. Biol. Chem."},{"key":"38394_CR5","first-page":"118","volume":"4","author":"SV Silva","year":"2000","unstructured":"Silva, S. V., Fujiwara, P. I. & Frieden, T. R. Rates and risk factors for discontinuation of rifampicin. Int. J. Tuberc. Lung Dis. 4, 118\u2013122 (2000).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"38394_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/jac\/3.2.115","volume":"3","author":"DJ Girling","year":"1977","unstructured":"Girling, D. J. Adverse reactions to rifampicin in antituberculosis regimens. J. Antimicrob. Chemother. 3, 115\u2013132. https:\/\/doi.org\/10.1093\/jac\/3.2.115 (1977).","journal-title":"J. Antimicrob. Chemother."},{"key":"38394_CR7","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment, <https:\/\/www.who.int\/publications\/i\/item\/9789240007048> (2020)."},{"key":"38394_CR8","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/s0140-6736(22)01883-9","volume":"400","author":"J Mok","year":"2022","unstructured":"Mok, J. et al. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): A multicentre, randomised, open-label phase 2\/3 non-inferiority trial in South Korea. The Lancet 400, 1522\u20131530. https:\/\/doi.org\/10.1016\/s0140-6736(22)01883-9 (2022).","journal-title":"The Lancet"},{"key":"38394_CR9","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","volume":"387","author":"BT Nyang'wa","year":"2022","unstructured":"Nyang\u2019wa, B. T. et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N. Engl. J. Med. 387, 2331\u20132343. https:\/\/doi.org\/10.1056\/NEJMoa2117166 (2022).","journal-title":"N. Engl. J. Med."},{"key":"38394_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02078-5","author":"RL Goodall","year":"2022","unstructured":"Goodall, R. L. et al. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): An open-label, multicentre, randomised, non-inferiority trial. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(22)02078-5 (2022).","journal-title":"Lancet"},{"key":"38394_CR11","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","volume":"205","author":"A Esmail","year":"2022","unstructured":"Esmail, A. et al. An all-oral 6-month regimen for multidrug-resistant tuberculosis: A multicenter, randomized controlled clinical trial (the next study). Am. J. Respir. Crit. Care Med. 205, 1214\u20131227. https:\/\/doi.org\/10.1164\/rccm.202107-1779OC (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"38394_CR12","unstructured":"Korea Disease Control and Prevention Agency. Korean Guidelines for Tuberculosis, 4th edition. (2020)."},{"key":"38394_CR13","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","volume":"8","author":"Z Lan","year":"2020","unstructured":"Lan, Z. et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: An individual patient data meta-analysis. Lancet Respir. Med. 8, 383\u2013394. https:\/\/doi.org\/10.1016\/S2213-2600(20)30047-3 (2020).","journal-title":"Lancet Respir. Med."},{"key":"38394_CR14","doi-asserted-by":"publisher","first-page":"ofab018","DOI":"10.1093\/ofid\/ofab018","volume":"8","author":"JH Malenfant","year":"2021","unstructured":"Malenfant, J. H. & Brewer, T. F. Rifampicin mono-resistant tuberculosis-a review of an uncommon but growing challenge for global tuberculosis control. Open Forum Infect. Dis. 8, ofab018. https:\/\/doi.org\/10.1093\/ofid\/ofab018 (2021).","journal-title":"Open Forum Infect. Dis."},{"key":"38394_CR15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01467-2019","author":"S Abidi","year":"2020","unstructured":"Abidi, S. et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.01467-2019 (2020).","journal-title":"Eur. Respir. J."},{"key":"38394_CR16","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","volume":"380","author":"AJ Nunn","year":"2019","unstructured":"Nunn, A. J. et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N. Engl. J. Med. 380, 1201\u20131213. https:\/\/doi.org\/10.1056\/NEJMoa1811867 (2019).","journal-title":"N. Engl. J. Med."},{"key":"38394_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/ACI.0000000000000462","volume":"18","author":"S Nagarajan","year":"2018","unstructured":"Nagarajan, S. & Whitaker, P. Management of adverse reactions to first-line tuberculosis antibiotics. Curr. Opin. Allergy Clin. Immunol. 18, 333\u2013341 (2018).","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"38394_CR18","first-page":"25","volume":"2","author":"L Meena","year":"2012","unstructured":"Meena, L., Rai, M., Pathak, A., Garg, S. & Bharti, A. Rifampicin-induced fever. IOSR J. Pharm. Biol. Sci. 2, 25\u201326 (2012).","journal-title":"IOSR J. Pharm. Biol. Sci."},{"key":"38394_CR19","unstructured":"Korea Disease Control and Prevention Agency. Korean Guidelines for Tuberculosis, 1st edition. (2005)."},{"key":"38394_CR20","unstructured":"Korea Disease Control and Prevention Agency. Korean Guidelines for Tuberculosis, 2nd edition. (2014)."},{"key":"38394_CR21","unstructured":"Korea Disease Control and Prevention Agency. Korean Guidelines for Tuberculosis, 3rd edition. (2017)."},{"key":"38394_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/cid\/ciw566","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid, P. et al. Executive summary: Official American thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clin. Infect. Dis. 63, 853\u2013867. https:\/\/doi.org\/10.1093\/cid\/ciw566 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"38394_CR23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00804-2021","author":"NN Linh","year":"2021","unstructured":"Linh, N. N. et al. World Health Organization treatment outcome definitions for tuberculosis: 2021 update. Eur. Respir. J. https:\/\/doi.org\/10.1183\/13993003.00804-2021 (2021).","journal-title":"Eur. Respir. J."},{"key":"38394_CR24","doi-asserted-by":"publisher","first-page":"e1380","DOI":"10.1016\/S2214-109X(21)00300-4","volume":"9","author":"L Chenciner","year":"2021","unstructured":"Chenciner, L., Annerstedt, K. S., Pescarini, J. M. & Wingfield, T. Social and health factors associated with unfavourable treatment outcome in adolescents and young adults with tuberculosis in Brazil: A national retrospective cohort study. Lancet Glob Health 9, e1380\u2013e1390. https:\/\/doi.org\/10.1016\/S2214-109X(21)00300-4 (2021).","journal-title":"Lancet Glob Health"},{"key":"38394_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.rmed.2017.08.002","volume":"131","author":"S Park","year":"2017","unstructured":"Park, S., Jo, K. W., Lee, S. D., Kim, W. S. & Shim, T. S. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. Respir. Med. 131, 43\u201348. https:\/\/doi.org\/10.1016\/j.rmed.2017.08.002 (2017).","journal-title":"Respir. Med."},{"key":"38394_CR26","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/nep.13816","volume":"26","author":"KL Gupta","year":"2021","unstructured":"Gupta, K. L. et al. Levofloxacin based non-rifampicin anti-tuberculous therapy: An effective alternative in renal transplant recipients in resource limited setting. Nephrology (Carlton) 26, 178\u2013184. https:\/\/doi.org\/10.1111\/nep.13816 (2021).","journal-title":"Nephrology (Carlton)"},{"key":"38394_CR27","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa2212537","volume":"388","author":"NI Paton","year":"2023","unstructured":"Paton, N. I. et al. Treatment strategy for rifampin-susceptible tuberculosis. N. Engl. J. Med. 388, 873\u2013887. https:\/\/doi.org\/10.1056\/NEJMoa2212537 (2023).","journal-title":"N. Engl. J. Med."},{"key":"38394_CR28","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2104535","volume":"386","author":"A Turkova","year":"2022","unstructured":"Turkova, A. et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N. Engl. J. Med. 386, 911\u2013922. https:\/\/doi.org\/10.1056\/NEJMoa2104535 (2022).","journal-title":"N. Engl. J. Med."},{"key":"38394_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/arrd.1981.123.4.367","volume":"123","author":"JM Dickinson","year":"1981","unstructured":"Dickinson, J. M. & Mitchison, D. A. Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am. Rev. Respir. Dis. 123, 367\u2013371. https:\/\/doi.org\/10.1164\/arrd.1981.123.4.367 (1981).","journal-title":"Am. Rev. Respir. Dis."},{"key":"38394_CR30","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1164\/arrd.1980.121.6.939","volume":"121","author":"A Jindani","year":"1980","unstructured":"Jindani, A., Aber, V. R., Edwards, E. A. & Mitchison, D. A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121, 939\u2013949. https:\/\/doi.org\/10.1164\/arrd.1980.121.6.939 (1980).","journal-title":"Am. Rev. Respir. Dis."},{"key":"38394_CR31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.transproceed.2011.12.065","volume":"44","author":"HE Yoon","year":"2012","unstructured":"Yoon, H. E. et al. Safety and efficacy of a quinolone-based regimen for treatment of tuberculosis in renal transplant recipients. Transpl. Proc. 44, 730\u2013733. https:\/\/doi.org\/10.1016\/j.transproceed.2011.12.065 (2012).","journal-title":"Transpl. Proc."},{"key":"38394_CR32","unstructured":"Curry International Tuberculosis Center and California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians, 3rd edition, <https:\/\/www.currytbcenter.ucsf.edu\/products\/cover-pages\/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition> (2016)."},{"key":"38394_CR33","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/febs.12108","volume":"280","author":"GA Prosser","year":"2013","unstructured":"Prosser, G. A. & de Carvalho, L. P. Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by the antibiotic D-cycloserine. FEBS J. 280, 1150\u20131166. https:\/\/doi.org\/10.1111\/febs.12108 (2013).","journal-title":"FEBS J."},{"key":"38394_CR34","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1056\/NEJMra1413919","volume":"373","author":"CR Horsburgh Jr","year":"2015","unstructured":"Horsburgh, C. R. Jr., Barry, C. E. 3rd. & Lange, C. Treatment of tuberculosis. N. Engl. J. Med. 373, 2149\u20132160. https:\/\/doi.org\/10.1056\/NEJMra1413919 (2015).","journal-title":"N. Engl. J. Med."},{"key":"38394_CR35","first-page":"241","volume":"14","author":"AJ Nunn","year":"2010","unstructured":"Nunn, A. J., Phillips, P. P. & Mitchison, D. A. Timing of relapse in short-course chemotherapy trials for tuberculosis. Int. J. Tuberc. Lung Dis. 14, 241\u2013242 (2010).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"38394_CR36","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","volume":"371","author":"SH Gillespie","year":"2014","unstructured":"Gillespie, S. H. et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371, 1577\u20131587. https:\/\/doi.org\/10.1056\/NEJMoa1407426 (2014).","journal-title":"N. Engl. J. Med."},{"key":"38394_CR37","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1056\/NEJMoa1315817","volume":"371","author":"CS Merle","year":"2014","unstructured":"Merle, C. S. et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N. Engl. J. Med. 371, 1588\u20131598. https:\/\/doi.org\/10.1056\/NEJMoa1315817 (2014).","journal-title":"N. Engl. J. Med."},{"key":"38394_CR38","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","volume":"371","author":"A Jindani","year":"2014","unstructured":"Jindani, A. et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N. Engl. J. Med. 371, 1599\u20131608. https:\/\/doi.org\/10.1056\/NEJMoa1314210 (2014).","journal-title":"N. Engl. J. Med."},{"key":"38394_CR39","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1111\/febs.15582","volume":"288","author":"G Arora","year":"2021","unstructured":"Arora, G., Bothra, A., Prosser, G., Arora, K. & Sajid, A. Role of post-translational modifications in the acquisition of drug resistance in Mycobacterium tuberculosis. Febs. J. 288, 3375\u20133393. https:\/\/doi.org\/10.1111\/febs.15582 (2021).","journal-title":"Febs. J."},{"key":"38394_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02220-16","author":"XA Kayigire","year":"2017","unstructured":"Kayigire, X. A., Friedrich, S. O., van der Merwe, L. & Diacon, A. H. Acquisition of rifampin resistance in pulmonary tuberculosis. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02220-16 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"38394_CR41","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nri3813","volume":"15","author":"RS Wallis","year":"2015","unstructured":"Wallis, R. S. & Hafner, R. Advancing host-directed therapy for tuberculosis. Nat. Rev. Immunol. 15, 255\u2013263. https:\/\/doi.org\/10.1038\/nri3813 (2015).","journal-title":"Nat. Rev. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38394-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38394-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38394-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T23:06:05Z","timestamp":1689203165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38394-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38394"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-38394-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]},"assertion":[{"value":"31 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11275"}}